Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

9.825 -0.045 (-0.46%)
Streaming Delayed Price Updated: 1:28 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >
3 of Wall Street’s Favorite Stocks We Find Risky
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns. 
Via Benzinga
Topics Government World Trade
1 Small-Cap Stock with Competitive Advantages and 2 We Turn Down
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
From Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma
Via Business Wire
Earnings Scheduled For August 5, 2025
 
Via Benzinga
A Peek at Amneal Pharmaceuticals's Future Earnings
 
Via Benzinga
3 Lesser-Known Healthcare Names With Major Upside in Store
These are three healthcare stocks offering a compelling combination of secure business, strong fundamentals, and growth opportunity. 
Via MarketBeat
Amneal to Report Third Quarter 2025 Results on October 30, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops
Amneal’s bimatoprost ophthalmic solution 0.01% is indicated for the reduction of high eye pressure in patients with certain eye conditions. 
Via Stocktwits
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segment 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
3 Low-Volatility Stocks We Find Risky
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Topics Economy Government World Trade
Why Amneal (AMRX) Stock Is Up Today
Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 4.7% in the afternoon session after the company announced it received U.S. Food and Drug Administration (FDA) approval for... 
Via StockStory
Topics Artificial Intelligence Economy
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
Expands Amneal’s Affordable Medicines portfolio and broadens patient access 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
3 Hyped Up Stocks with Open Questions
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
1 Cash-Producing Stock for Long-Term Investors and 2 We Turn Down
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Topics Bonds
Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Artificial Intelligence Economy
AMRX Q2 Deep Dive: New Product Launches and Specialty Momentum Shape Guidance
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) missed Wall Street’s revenue expectations in Q2 CY2025 as sales rose 3.2% year on year to $724.5 million. On the other hand, the company’s... 
Via StockStory
Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed... 
Via StockStory
Topics Bonds Economy Stocks
1 Value Stock to Keep an Eye On and 2 Facing Challenges
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Amneal (AMRX) Q2 EPS Jumps 56%
Via The Motley Fool
Topics Economy
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Mixed Q2 2025 Results: Earnings Beat, Revenue Miss
Amneal Pharmaceuticals (AMRX) reported mixed Q2 2025 results, with EPS beating estimates but revenue missing. Shares dipped slightly as investors weighed strong profitability against softer sales.... 
Via Chartmill
Topics Earnings
Amneal (NASDAQ:AMRX) Misses Q2 Sales Targets
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell short of the market’s revenue expectations in Q2 CY2025 as sales rose 3.2% year on year to $724.5 million. On the other hand, the... 
Via StockStory
Amneal Reports Second Quarter 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Earnings: What To Look For From AMRX
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Tuesday before the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Government World Trade
Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
3 Profitable Stocks with Warning Signs
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.